Recombinant Human Adenomatous Polyposis Coli Protein (APC) Protein (His&Myc)

Beta LifeScience SKU/CAT #: BLC-06988P
Greater than 85% as determined by SDS-PAGE.
Greater than 85% as determined by SDS-PAGE.

Recombinant Human Adenomatous Polyposis Coli Protein (APC) Protein (His&Myc)

Beta LifeScience SKU/CAT #: BLC-06988P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description Recombinant Human Adenomatous Polyposis Coli Protein (APC) Protein (His&Myc) is produced by our E.coli expression system. This is a protein fragment.
Purity Greater than 85% as determined by SDS-PAGE.
Uniprotkb P25054
Target Symbol APC
Species Homo sapiens (Human)
Expression System E.coli
Tag N-10His&C-Myc
Target Protein Sequence SNDSLNSVSSSDGYGKRGQMKPSIESYSEDDESKFCSYGQYPADLAHKIHSANHMDDNDGELDTPINYSLKYSDEQLNSGRQSPSQNERWARPKHIIEDEIKQSEQRQSRNQSTTYPVYTESTDDKHLKFQPHFGQQECVSPYRSRGANGSETNRVGSNHGINQNVSQSLCQEDDYEDDKPTNYSERYSEEEQHEEEERPTNYSIKYNEEKRHVDQPIDYSLKYATDIPSSQKQSFSFSKSSSGQSSKTEHMSSSSENTSTPSSNAKRQNQLHPSSAQSRSGQPQKAATCKVSSINQETIQTYCVEDTPICFSRCSSLSSLSSAEDEIGCNQTTQEADSANTLQIAEIKEKIGTRSAEDPVSEVPAVSQHPRTKSSRL
Expression Range 960-1337aa
Protein Length Partial
Mol. Weight 49.8 kDa
Research Area Cancer
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function Tumor suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signaling as a negative regulator. APC activity is correlated with its phosphorylation state. Activates the GEF activity of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)-induced cell migration. Required for MMP9 up-regulation via the JNK signaling pathway in colorectal tumor cells. Acts as a mediator of ERBB2-dependent stabilization of microtubules at the cell cortex. It is required for the localization of MACF1 to the cell membrane and this localization of MACF1 is critical for its function in microtubule stabilization.
Subcellular Location Cell junction, adherens junction. Cytoplasm, cytoskeleton. Cell projection, lamellipodium. Cell projection, ruffle membrane. Cytoplasm. Cell membrane.
Protein Families Adenomatous polyposis coli (APC) family
Database References
Associated Diseases Familial adenomatous polyposis (FAP); Hereditary desmoid disease (HDD); Medulloblastoma (MDB); Gastric cancer (GASC); Hepatocellular carcinoma (HCC)
Tissue Specificity Expressed in a variety of tissues: brain, small intestine, colon, thymus, skeletal muscle, heart, prostate, lung, spleen, ovary, testis kidney, placenta, blood and liver. Isoform 1A: Very strongly expressed in brain but has relatively low expression level

Gene Functions References

  1. elevated expression of miR-494 promotes cell proliferation and tumorigenesis in CRC by suppressing the expression of APC, an inhibitor of beta-catenin signaling. These findings uncover a novel molecular mechanism for the hyperactivation of the Wnt/beta-catenin signaling pathway in CRC. PMID: 29304823
  2. Study reveal an unexpected role of APC in the directional spread of HIV-1 by promoting the directional assembly of viral components at virological synapses, thereby facilitating cell-to-cell viral transmission. PMID: 28134256
  3. Because of low sensitivity, APC gene promoter methylation in serum was not suitable for breast cancer (BC) screening. However, as specificity was very high, detection of serum APC gene promoter methylation could be used as tool to confirm BC. PMID: 29297603
  4. Multivariate analyses revealed that the PIK3CA mutation and clinical T stage were independent favorable prognostic factors (hazard ratio 0.34, 95% confidence interval: 0.12-0.96, p = 0.042). PIK3CA mutations were significantly associated with APC alterations (p = 0.0007) and BRAF mutations (p = 0.0090). PMID: 30115035
  5. A novel APC frameshift mutation has been identified in a large Chinese family with familial adenomatous polyposis. PMID: 29901124
  6. In the two wild type (WT) cases, two novel alterations were detected: a complex deletion of APC and a pathogenic mutation of LAMTOR2. Focusing on WT DT subtype, deep sequencing of CTNNB1, APC and LAMTOR2 was conducted on a retrospective series of 11 WT DT using a targeted approach PMID: 29901254
  7. This study demonstrates a prognostic role for APC. PMID: 27302369
  8. There is a certain correlation between the APC gene and ovarian tumors, and the APC gene mediates the apoptosis of tumor cells through the MDR-1/CLCX-1 signaling pathway. PMID: 29921377
  9. Its mutation is identified in duodenal adenoma and it involves in development of duodenal cancers. PMID: 29525853
  10. We have investigated if the initial source of intratumoral heterogeneity is consequent to multiple independent lineages derived from different crypts harboring distinct truncal APC and driver KRAS mutations, thus challenging the prevailing monoclonal monocryptal model. PMID: 28645942
  11. methylation-dependent silencing of the APC gene promoter 1A is a mechanism that contributes to the activation of Wnt signaling pathway in cervical cancer cells infected by high risk HPV16. PMID: 29115417
  12. miR-3607 contributes to lung cancer cell proliferation by inhibiting APC. PMID: 28866416
  13. USP7 depletion in APC-mutated colorectal cancer inhibits Wnt activation by restoring beta-catenin ubiquitination, drives differentiation, and suppresses xenograft tumor growth. PMID: 29045831
  14. Data suggest that the concurrent mutations of the adenomatous polyposis coli protein (APC) and mutL protein homolog 1 (MLH1) genes probably underline the familial adenomatous polyposis (FAP) in the pedigree. PMID: 29419868
  15. The expression of APC-DeltaC in colon cells reduces the accumulation of mitotic cells upon PLK1 inhibition, accelerates mitotic exit and increases the survival of cells with enhanced chromosomal abnormalities. PMID: 29549256
  16. our results suggest that the amount of APC expression is the rate-limiting factor for the constitution of beta-catenin destruction complexes. PMID: 28810742
  17. APC defines Treg differentiation and anti-inflammatory function through microtubule-mediated NFAT localization. PMID: 28978472
  18. Data show that tumor suppressor adenomatous polyposis coli (APC) loss results in up-regulation of IL-6 signal transducer (IL-6ST/gp130), thereby activating YAP (YY1-associated) protein (YAP) which are simultaneously up-regulated in the majority of colorectal cancer (CRC). PMID: 28130546
  19. The results indicate that APC promoter hypermethylation is an early event in carcinogenesis of CRC, could be a valuable diagnostic marker for early-stage CRC. APC methylation is not significantly associated with overall survival in patients with CRC. PMID: 28515349
  20. the promoters of WIF1, NLK, and APC are highly methylated in the nasopharyngeal cancers (NPC) and gastric carcinoma (GC) cell lines, and the 3 genes are also regulated by miR-BART19-3p expressed by Epstein-Barr virus (EBV); expression of the WIF1, APC, and NLK genes is strongly affected by hypermethylation, and in EBV-associated tumors, the 3 genes are also affected by miR-BART19-3p PMID: 28543390
  21. The model we propose is a variation of the currently existing model and hypothesizes that, in a subgroup of colorectal carcinomas, K-ras mutation may precede APC inactivation, representing the earliest driving force and, probably, an early biomarker of colorectal carcinogenesis. PMID: 28652417
  22. We conclude that among multiple genomic alterations in CRC, strongest associations with clinical outcome were observed for common mutations in APC. PMID: 27729614
  23. Studies reveal that the proportion of APC promoter 1A methylation in non-small cell lung cancer (NSCLC) tissues was higher than in autologous controls, indicating that promoter 1A methylation of the APC gene may play an important role in NSCLC carcinogenesis. [meta-analysis] PMID: 28497891
  24. E-cadherin inhibits beta-catenin in the context of disruption of the APC-destruction complex, and that this function is also EC1 domain dependent. Both binding functions of E-cadherin may be required for its tumour suppressor activity. PMID: 27566565
  25. analysis of the largest deletion of the APC gene in the Chinese population associated with familial adenomatous polyposis in a five generation family PMID: 27391059
  26. APC promoter methylation was associated with breast cancer risk, and it could be a valuable biomarker for diagnosis, treatment and prognosis of breast cancer (Meta-Analysis) PMID: 27191268
  27. A novel APC promoter 1B deletion is associated with familial adenomatous polyposis in generations of a large Italian family. PMID: 28791770
  28. Study is the first to demonstrate that EphB6 overexpression together with Apc gene mutations may enhance proliferation, invasion and metastasis by colorectal epithelial cells. PMID: 27145271
  29. Promoter methylation was detected in 30.67% breast cancer tissues and was associated with low histological grade. PMID: 28164568
  30. Utilizing zebrafish to examine the genetic relationship between MPC1 and Adenomatous polyposis coli (APC), a key tumor suppressor in colorectal cancer, the authors found that apc controls the levels of mpc1 and that knock down of mpc1 recapitulates phenotypes of impaired apc function including failed intestinal differentiation. PMID: 28397687
  31. Multiple pilomatrixomas in a survivor of WNT-activated medulloblastoma leading to the discovery of a germline APC mutation and the diagnosis of familial adenomatous polyposis PMID: 28792655
  32. FZR1 inhibits BRAF oncogenic functions via both APC-dependent proteolysis and APC-independent disruption of BRAF dimers, whereas hyperactivated ERK and CDK4 reciprocally suppress APC(FZR1) E3 ligase activity PMID: 28174173
  33. we present a clinical molecular study of a four generation Chinese family with a novel splice-acceptor site mutation causing Familial adenomatous polyposis PMID: 28423518
  34. Establish a role for APC in coordinating microtubules and actin cytoskeleton at focal adhesions to direct cell migration. PMID: 28663347
  35. Germline mutation in the APC gene is associated with familial adenomatous polyposis. PMID: 28010732
  36. beta-catenin reactivity was noted in all familial adenomatous polyposis-associated Gardner fibromas and in 1/4 APC wild-type cases PMID: 26840078
  37. The rs75612255 C allele and rs113017087 C allele in promoter 1A of APC as well as the rs138386816 T allele and rs115658307 T allele in promoter 1B of APC significantly increased luciferase activity in the human erythromyeloblastoid leukaemia cell line K562. PMID: 28105931
  38. Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumorigenesis in murine mammary epithelium PMID: 27694902
  39. Finally, we observed that expression of miR-19a significantly correlates with beta-catenin levels in colorectal cancer specimens, and it is associated to the aggressive stage of tumor progression. Thus, our study reveals that miR-17-92 cluster is directly regulated by APC/b-catenin pathway and could be a potential therapeutic target in colon cancers with aberrant APC/b-catenin signaling. PMID: 26804172
  40. Findings show that colorectal Cancer patients-derived cells with short APC mutants were either sensitive or responsive to tankyrase inhibitors corroborating the idea that APC with complete deletion of seven 20-AA repeats could be a predictive biomarker for the sensitivity to tankyrase inhibitors. PMID: 28179481
  41. Our study showed that mutations in the APC gene alter the protein expression and cell cycle regulation in diffuse type gastric adenocarcinoma. PMID: 28576136
  42. Gasdermin C is upregulated by inactivation of Tgfbr2 in the presence of mutated Apc, promoting colorectal cancer cell proliferation. PMID: 27835699
  43. Nine patients with 21- approximately 100 colorectal adenomas (50%) and the two positive controls, showed somatic mosaicism, with identical APC variants in adenomas tested. PMID: 27816598
  44. These result suggested that miR-590-3p can promote osteogenic differentiation via suppressing APC expression and stabilizing beta-catenin. PMID: 27586273
  45. The present findings indicate epigenetic silencing of APC in advanced gallbladder cancer (GBC). The methylation pattern, followed by expression analysis of APC may be suggested for diagnostic, prognostic and therapeutic purposes in GBC in future PMID: 27748282
  46. miR-106a-5p is involved in the invasive behavior of glioblastoma cells and by targeting APC and activating Wnt/beta-catenin pathway. PMID: 27815074
  47. Point Mutations in Exon 1B of APC Reveal Similar mutations in APC promoter 1B occur in rare families with familial adenomatous polyposis PMID: 27087319
  48. Studies suggest that both loss of tumor suppressive function and gain of function of APC mutants play critical roles in colorectal cancers (CRC) tumorigenesis. PMID: 28423402
  49. Loss of heterozygosity of TP53, P16, SMAD4 and APC genes was observed in esophageal adenocarcinoma. PMID: 28376920
  50. miR-582-5P was upregulated in the colorectal cancer specimens and cell lines and targeted the 3' untranslated region of APC directly. PMID: 27595705

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed